TNKase (T-N-Kase, tenecteplase), a new thrombolytic for treating heart attacks

July 2000

Genentech is now introducing TNKase (T-N-Kase, tenecteplase), a new thrombolytic for treating heart attacks.

TNKase is a modified version of Activase (alteplase, tPA). It's made by substituting 3 amino acids of the tPA enzyme.

TNKase and Activase have comparable efficacy for restoring blood flow and improving survival after a heart attack.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

get package inserts electronically
Gastroenterology new proton pump inhibitor, Protonix (pantoprazole)
Stroke most patients should get aspirin for an acute ischemic stroke
Women's Health lengthening oral contraceptive cycles
Women's Health taking low-dose oral contraceptives right up until menopause
Women's Health Activella, a new combo HRT tablet for postmenopausal women
new guidelines for treating asthma during pregnancy
Allergic Reactions which drugs might cause problems in patients with sulfa allergies
Cynara-SL, a new dietary supplement made from artichokes
Men's Health PC-SPES (pea-see spehz) for prostate cancer
Men's Health Gonal-F is now approved for treating infertility in MEN
Cardiology TNKase (T-N-Kase, tenecteplase), a new thrombolytic for treating heart attacks
Cardiology Betapace AF, a new version of sotalol for atrial fibrillation
Cardiology more aggressive treatment of SYSTOLIC hypertension
Cholesterol start statins EARLIER after a heart attack
Practice splendid review of our Natural Medicines Comprehensive Database
Infectious Diseases new guidelines for treating latent tuberculosis